-
Xeljanz FDA Drug Safety Communication in February 2021 Puts Heightened Scrutiny on Pfizer
One wonders how the FDA might react to this continued “direct to consumer” advertising for Xeljanz which Pfizer is (still) sponsoring after the February 2021 FDA Xeljanz Drug Safety Communication about Xeljanz causing heart…
-
Beovu Side Effects Have Caused Eye Doctors to Avoid Beovu and Use Other Safer AMD Drugs Instead
In Addition, the Three New Beovu Lawsuits Filed for Patients with Vision Loss May Further Impact Novartis Market Share (Posted by Tom Lamb at Drug Injury Watch) Since being approved by the…
-
Elmiron Maculopathy Secondary to Pentosan Polysulfate (PPS) Toxicity: Medical Journal Article
New Elmiron Study Suggests Established Maculopathy Patients Should be Asked About Possible Elmiron Use (Posted by Tom Lamb at Drug Injury Watch) Elmiron maculopathy secondary to pentosan polysulfate (PPS) toxicity was first…
-
Gilenya Liver Injury Risk Warnings Are Increased, Again, This Time in Canada
Similar Gilenya Drug Label Changes Were Made in Europe and UK During Past Few Months (Posted by Tom Lamb at Drug Injury Watch) On January 18, 2021 Health Canada posted a Gilenya…